Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Mar 1;72(3):439-446.
doi: 10.4103/IJO.IJO_2317_23. Epub 2024 Jan 8.

Outcome of combined trabeculectomy with cataract surgery in patients on prostaglandin analogs and aqueous suppressants

P R Aswin  1 , Neethu Mohan  2 , Balagiri Sundar  3 , Arvin Kurian Ponnat  4 , Shanthi Radhakrishnan  5 , Subbaiah R Krishnadas  4 , Emily Schehlein  6
Affiliations

Outcome of combined trabeculectomy with cataract surgery in patients on prostaglandin analogs and aqueous suppressants

P R Aswin et al. Indian J Ophthalmol. .

Abstract

Purpose: To compare the effect of prostaglandin analogs (PGA) against other glaucoma medications (non-PGA) on the intraocular pressure (IOP) outcomes of combined trabeculectomy with phacoemulsification, and the conjunctival cell profile in persons with primary open-angle (POAG) and pseudoexfoliation glaucoma (PXFG).

Methods: A prospective cohort study was conducted among 116 patients with POAG or PXFG on glaucoma medications for a minimum of 3 months undergoing glaucoma triple procedure. Patients were divided into two groups (PGA and non-PGA) based on preoperative exposure to PGA. IOP outcomes were assessed for up to 2 years. Conjunctival biopsy specimens were obtained at the time of surgery, and histopathological analysis was performed.

Results: Forty-two patients were in the PGA group, 67 were in the non-PGA group, and seven were lost to follow-up. The non-PGA group had lesser mean postoperative IOP and needed fewer postoperative medications compared to the PGA group in all visits up to 2 years. The non-PGA group had better complete success rate (50.7% vs. 14.3%, P < 0.001). Kaplan-Meier survival estimates showed a significant difference in cumulative complete success rate between non-PGA (67%) and PGA (26%) by 24 months ( P < 0.001). The Cox proportional model showed the type of drug to be significantly associated with surgical failure. Histopathological analysis revealed that the PGA group had higher numbers for each type of inflammatory cell (except mast cells) compared to the non-PGA group.

Conclusion: Patients on PGA are likely to have a higher postoperative IOP and may need more medications for IOP control after a glaucoma triple procedure.

PubMed Disclaimer

Conflict of interest statement

There are no conflicts of interest.

Figures

Figure 1
Figure 1
Line graph showing the pressure variation among the PGA and non-PGA groups at various time periods
Figure 2
Figure 2
Kaplan–Meier survival curve showing the cumulative probability of complete success (a) and probability of qualified success (b) between the PGA and non-PGA groups
Figure 3
Figure 3
Histopathological images of the conjunctival epithelium of (a) PGA group – goblet cells with mucinous cytoplasm and eccentric nuclei (circled) (H and E 400×) and mast cells with eosinophilic, granular cytoplasm, and small central or eccentric nuclei (yellow arrow) (b) PGA group – showing diffuse vascular congestion and inflammatory cell infiltration of epithelium and substantia propria (200×) (c) Non-PGA group – showing mild acanthosis and a few scattered inflammatory cells (200×)
See this image and copyright information in PMC

References

    1. Kass MA, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JL, Miller JP, et al. The ocular hypertension treatment study: A randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120:701–13. discussion 829-30. - PubMed
    1. Heijl A, Leske MC, Bengtsson B, Hyman L, Bengtsson B, Hussein M, et al. Reduction of intraocular pressure and glaucoma progression: Results from the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2002;120:1268–79. - PubMed
    1. Leske MC, Heijl A, Hussein M, Bengtsson B, Hyman L, Komaroff E, et al. Factors for glaucoma progression and the effect of treatment: The early manifest glaucoma trial. Arch Ophthalmol. 2003;121:48–56. - PubMed
    1. Anderson DR; Normal Tension Glaucoma Study Collaborative normal tension glaucoma study. Curr Opin Ophthalmol. 2003;14:86–90. - PubMed
    1. Leske MC, Heijl A, Hyman L, Bengtsson B, Komaroff E. Factors for progression and glaucoma treatment: The early manifest glaucoma trial. Curr Opin Ophthalmol. 2004;15:102–6. - PubMed

MeSH terms

Substances